An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

20191,058 citationsJournal Articlebronze Open Access

Authors

Kevan C. Herold · Yale University

Brian N. Bundy · University of South Florida

S. Alice Long · Benaroya Research Institute

Jeffrey A. Bluestone · University of California, San Francisco

Linda A. DiMeglio · Indiana University – Purdue University Indianapolis

Matthew J. Dufort · Benaroya Research Institute

Stephen E. Gitelman

Abstract

Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01030861.).

Topics & Keywords

Diabetes and associated disorders Diabetes Management and Research Pancreatic function and diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 381, Issue 7, pp. 603-613

DOI: 10.1056/nejmoa1902226

Field-Weighted Citation Impact: 72.52